{"id":"lupron-depot","safety":{"commonSideEffects":[{"rate":"60–80","effect":"Hot flashes"},{"rate":"40–60","effect":"Decreased libido"},{"rate":"40–60","effect":"Erectile dysfunction"},{"rate":"5–15","effect":"Injection site reaction"},{"rate":null,"effect":"Bone density loss (osteoporosis with long-term use)"},{"rate":"20–40","effect":"Fatigue"}]},"_chembl":null,"_dailymed":{"setId":"e99f47d2-da10-3127-ecb3-e5d942ae6e81","title":"LUPRON DEPOT-PED (LEUPROLIDE ACETATE) KIT [ABBVIE INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lupron Depot works by initially stimulating GnRH receptors on pituitary gonadotroph cells, causing a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous exposure, the pituitary becomes desensitized, leading to sustained suppression of LH and FSH, which results in dramatically reduced testosterone (in males) and estrogen (in females). This hormonal suppression is used therapeutically in hormone-sensitive cancers and other conditions dependent on sex hormone signaling.","oneSentence":"Lupron Depot is a gonadotropin-releasing hormone (GnRH) agonist that suppresses testosterone and estrogen production by desensitizing the pituitary gland.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:46.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"}]},"trialDetails":[{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT06169124","phase":"PHASE2","title":"Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-08","conditions":"Adult Ovarian Granulosa Cell Tumor","enrollment":37},{"nctId":"NCT07027124","phase":"PHASE2","title":"Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03-19","conditions":"Prostate Cancer, High-risk Prostate Cancer","enrollment":40},{"nctId":"NCT03573648","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-13","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT06654336","phase":"PHASE2","title":"Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)","status":"RECRUITING","sponsor":"Ontario Clinical Oncology Group (OCOG)","startDate":"2026-03-30","conditions":"Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer","enrollment":162},{"nctId":"NCT04557059","phase":"PHASE3","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-11-12","conditions":"Prostatic Neoplasms","enrollment":693},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":"Prostate Cancer, Localized Prostate Carcinoma","enrollment":50},{"nctId":"NCT05827081","phase":"PHASE3","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-28","conditions":"Early Breast Cancer","enrollment":1400},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":804},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":"Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer","enrollment":9},{"nctId":"NCT01786265","phase":"PHASE2","title":"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-05","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma","enrollment":310},{"nctId":"NCT06305598","phase":"PHASE1","title":"Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-12-19","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":14},{"nctId":"NCT02274779","phase":"PHASE2","title":"Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer","status":"COMPLETED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2014-08-20","conditions":"Prostate Cancer","enrollment":74},{"nctId":"NCT05320406","phase":"PHASE2","title":"RElugolix VErsus LeUprolide Cardiac Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-06-06","conditions":"Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8","enrollment":94},{"nctId":"NCT06627530","phase":"PHASE4","title":"COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2025-02-17","conditions":"Prostate Cancer","enrollment":144},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":"Breast Cancer","enrollment":1939},{"nctId":"NCT03902951","phase":"PHASE2","title":"Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-03-17","conditions":"Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma","enrollment":28},{"nctId":"NCT04734730","phase":"PHASE2","title":"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-05-04","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT04126070","phase":"PHASE2","title":"Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiao X. Wei, MD","startDate":"2020-05-11","conditions":"Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT03070886","phase":"PHASE2, PHASE3","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2017-04-05","conditions":"Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7","enrollment":612},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT05341115","phase":"PHASE4","title":"A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-03-14","conditions":"Central Precocious Puberty","enrollment":80},{"nctId":"NCT03056755","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-29","conditions":"Breast Cancer","enrollment":383},{"nctId":"NCT01746849","phase":"PHASE2","title":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Leukemia, Multiple Myeloma, Myelodysplastic Syndrome","enrollment":82},{"nctId":"NCT05122377","phase":"","title":"RWE About QOL and Compliance of Patients With OFS in China","status":"COMPLETED","sponsor":"Fudan University","startDate":"2022-03-01","conditions":"Breast Cancer, Quality of Life, Hormone Receptor-positive Breast Cancer","enrollment":562},{"nctId":"NCT03809000","phase":"PHASE2","title":"A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2019-04-15","conditions":"Prostate Cancer","enrollment":188},{"nctId":"NCT00329043","phase":"PHASE2","title":"Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-05-15","conditions":"Prostate Cancer","enrollment":64},{"nctId":"NCT05873192","phase":"PHASE2","title":"Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-06-03","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT03009981","phase":"PHASE3","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-03-06","conditions":"Prostate Cancer","enrollment":504},{"nctId":"NCT00001481","phase":"PHASE2","title":"The Role of Hormones in Postpartum Mood Disorders","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1996-04-26","conditions":"Postpartum Depression","enrollment":74},{"nctId":"NCT05669664","phase":"PHASE2","title":"Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-07-20","conditions":"Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma","enrollment":21},{"nctId":"NCT05493709","phase":"PHASE3","title":"Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foresee Pharmaceuticals Co., Ltd.","startDate":"2023-06-02","conditions":"Puberty; Precocious, Central","enrollment":93},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT03678025","phase":"PHASE3","title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-09-24","conditions":"Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":1273},{"nctId":"NCT07134920","phase":"","title":"Norethindrone Impact on Receptiva Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inception Fertility Research Institute, LLC","startDate":"2025-08-12","conditions":"Infertility (IVF Patients), Infertility Female","enrollment":700},{"nctId":"NCT05605964","phase":"PHASE3","title":"Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2023-01-25","conditions":"Prostate Cancer","enrollment":387},{"nctId":"NCT05765500","phase":"PHASE2","title":"RecoverPC: Relugolix vs GnRH Agonist in Quality of Life","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-12","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":110},{"nctId":"NCT04203381","phase":"NA","title":"Skeletal Health and Bone Marrow Composition Among Youth","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amy DiVasta, MD","startDate":"2020-09-15","conditions":"Gender Dysphoria in Children, Puberty, Bone Development","enrollment":80},{"nctId":"NCT03649724","phase":"PHASE2","title":"The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2020-11-27","conditions":"Alzheimer Disease, Mild Cognitive Impairment","enrollment":180},{"nctId":"NCT04760691","phase":"PHASE1","title":"Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2021-03-01","conditions":"Hiv, Prophylaxis, Transgender","enrollment":13},{"nctId":"NCT02319837","phase":"PHASE3","title":"Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2014-12-17","conditions":"Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate","enrollment":1068},{"nctId":"NCT06199986","phase":"NA","title":"DeADT - Living Well With Prostate Cancer","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT04249154","phase":"PHASE2","title":"Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2019-09-03","conditions":"Prostate Cancer","enrollment":77},{"nctId":"NCT02903368","phase":"PHASE2","title":"Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-10-19","conditions":"Prostate Cancer","enrollment":118},{"nctId":"NCT00001521","phase":"PHASE3","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-06-08","conditions":"Congenital Adrenal Hyperplasia (CAH)","enrollment":66},{"nctId":"NCT01673984","phase":"PHASE4","title":"GP Extended Action Triptorelin","status":"TERMINATED","sponsor":"Ipsen","startDate":"2012-08","conditions":"Prostate Cancer","enrollment":27},{"nctId":"NCT02278185","phase":"PHASE2","title":"Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-11-11","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer","enrollment":19},{"nctId":"NCT00544830","phase":"PHASE2","title":"Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2006-07-18","conditions":"PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7","enrollment":29},{"nctId":"NCT03703778","phase":"","title":"Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2016-05-22","conditions":"Prostate Cancer","enrollment":300},{"nctId":"NCT03361735","phase":"PHASE2","title":"Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-08-29","conditions":"Prostate Adenocarcinoma","enrollment":25},{"nctId":"NCT03951831","phase":"PHASE2","title":"REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mark Stein","startDate":"2019-05-16","conditions":"Prostate Cancer Metastatic","enrollment":26},{"nctId":"NCT06926933","phase":"PHASE4","title":"Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty","status":"RECRUITING","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2024-12-12","conditions":"CPP","enrollment":50},{"nctId":"NCT04302454","phase":"PHASE3","title":"Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2020-03-19","conditions":"Prostate Cancer","enrollment":280},{"nctId":"NCT00687739","phase":"PHASE3","title":"Prevention of Obesity in Women Via Estradiol Regulation","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2008-05","conditions":"Obesity","enrollment":79},{"nctId":"NCT05169112","phase":"PHASE3","title":"Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-03-06","conditions":"Prostate Cancer","enrollment":72},{"nctId":"NCT06855589","phase":"PHASE3","title":"Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.","status":"NOT_YET_RECRUITING","sponsor":"Charles LeMoyne Hospital","startDate":"2025-03","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":400},{"nctId":"NCT04445025","phase":"EARLY_PHASE1","title":"Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis","status":"COMPLETED","sponsor":"Colorado Center for Reproductive Medicine","startDate":"2020-09-01","conditions":"Infertility, Endometriosis","enrollment":30},{"nctId":"NCT00696111","phase":"NA","title":"Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2007-12","conditions":"Polycystic Ovary Syndrome, Obstructive Sleep Apnea","enrollment":18},{"nctId":"NCT06145438","phase":"PHASE3","title":"Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery","status":"COMPLETED","sponsor":"Universitas Diponegoro","startDate":"2023-09-04","conditions":"Endometriosis Ovary","enrollment":80},{"nctId":"NCT02588404","phase":"","title":"The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient","status":"WITHDRAWN","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2015-12","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT02685397","phase":"PHASE2, PHASE3","title":"Management of Castration-Resistant Prostate Cancer with Oligometastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2016-10","conditions":"Castration-resistant Prostate Cancer Patients with Oligometastases","enrollment":102},{"nctId":"NCT03035032","phase":"PHASE4","title":"A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2017-06-23","conditions":"Prostate Cancer","enrollment":107},{"nctId":"NCT02366494","phase":"","title":"Micro RNAs to Predict Response to Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2015-04-29","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT03047330","phase":"PHASE4","title":"Menopausal Sleep Fragmentation and Body Fat Gain","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-07-15","conditions":"Menopause","enrollment":41},{"nctId":"NCT01442246","phase":"PHASE3","title":"Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2011-07","conditions":"Metastases","enrollment":700},{"nctId":"NCT01921166","phase":"PHASE4","title":"Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2011-01","conditions":"Infertility","enrollment":23},{"nctId":"NCT02927392","phase":"NA","title":"Brown Adipose Tissue Activity in Pre- and Postmenopausal Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-03-16","conditions":"Menopause, Obesity","enrollment":69},{"nctId":"NCT01194271","phase":"PHASE2","title":"Neoadjuvant Ipilimumab in Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-09","conditions":"Prostate Cancer","enrollment":19},{"nctId":"NCT05568940","phase":"","title":"Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids","status":"WITHDRAWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-09","conditions":"Endometriosis, Fibroids","enrollment":""},{"nctId":"NCT03695237","phase":"PHASE3","title":"A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-10-24","conditions":"Central Precocious Puberty (CPP)","enrollment":45},{"nctId":"NCT03572387","phase":"PHASE2","title":"A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-08-20","conditions":"Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer","enrollment":14},{"nctId":"NCT03311555","phase":"PHASE2","title":"A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)","status":"COMPLETED","sponsor":"Andrew J. Armstrong, MD","startDate":"2018-03-28","conditions":"Prostate Cancer","enrollment":39},{"nctId":"NCT05574712","phase":"PHASE2","title":"A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-01-01","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT05149131","phase":"","title":"A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-01-17","conditions":"Metastatic Castration-sensitive Prostate Cancer","enrollment":960},{"nctId":"NCT00099086","phase":"PHASE1","title":"Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2007-01-16","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT00587431","phase":"PHASE2","title":"Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-07","conditions":"Prostate Cancer","enrollment":102},{"nctId":"NCT02203331","phase":"PHASE2","title":"Bay98-7196, Dose Finding / POC Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-10-16","conditions":"Endometriosis","enrollment":319},{"nctId":"NCT02941926","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-11-30","conditions":"Breast Cancer","enrollment":3246},{"nctId":"NCT01377389","phase":"PHASE2","title":"Ipilimumab + Androgen Depravation Therapy in Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-06-17","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT04051320","phase":"PHASE2","title":"Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2020-01-02","conditions":"Perinatal Depression, Post Partum Depression, Depression, Postpartum","enrollment":23},{"nctId":"NCT04914195","phase":"PHASE3","title":"Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Bharat Serums and Vaccines Limited","startDate":"2021-07-01","conditions":"Advanced Prostate Adenocarcinoma","enrollment":155},{"nctId":"NCT05937490","phase":"PHASE4","title":"Adenomyosis and ART","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2023-03-27","conditions":"Adenomyosis","enrollment":500},{"nctId":"NCT01326312","phase":"PHASE2","title":"Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer","status":"TERMINATED","sponsor":"GTx","startDate":"2011-06","conditions":"Prostate Cancer","enrollment":159},{"nctId":"NCT02058706","phase":"PHASE2","title":"LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2014-05","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer","enrollment":71},{"nctId":"NCT00203996","phase":"PHASE4","title":"Polycystic Ovary Syndrome (PCOS) and Sleep Apnea","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2003-09","conditions":"Polycystic Ovary Syndrome, Obstructive Sleep Apnea","enrollment":37},{"nctId":"NCT00001259","phase":"PHASE1","title":"A Treatment Study for Premenstrual Syndrome (PMS)","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1992-08-11","conditions":"Premenstrual Syndrome, Menstruation Disturbances","enrollment":60},{"nctId":"NCT03043807","phase":"PHASE2","title":"A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-02-22","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT03845751","phase":"PHASE2","title":"EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control.","status":"UNKNOWN","sponsor":"Institut Mutualiste Montsouris","startDate":"2023-01","conditions":"Prostate Cancer, Androgen Deprivation Therapy","enrollment":20},{"nctId":"NCT01642186","phase":"PHASE2","title":"Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-07-12","conditions":"Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer","enrollment":28},{"nctId":"NCT00694733","phase":"NA","title":"Regulation of Cortisol Metabolism and Fat Patterning","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2005-05","conditions":"Obesity, Menopausal Syndrome","enrollment":140},{"nctId":"NCT03856268","phase":"","title":"Understanding the Roles of Hormones in Adipocyte Remodeling Following Menopause","status":"WITHDRAWN","sponsor":"Pennington Biomedical Research Center","startDate":"2019-04-01","conditions":"Menopause Surgical, Estrogen Deficiency, Adiposity","enrollment":""},{"nctId":"NCT04239599","phase":"NA","title":"Trial of Hypofractionated IMRT Boost Versus Conventional IMRT Boost for Localized High Risk Prostate Cancer","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2011-03-31","conditions":"Prostate Cancer","enrollment":178},{"nctId":"NCT01960881","phase":"","title":"Evaluation of Diet and Exercise in Prostate Cancer Patients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-09-19","conditions":"Prostate Cancer","enrollment":1331},{"nctId":"NCT02716974","phase":"PHASE2","title":"A Study of Definitive Therapy to Treat Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-06","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT04225221","phase":"PHASE2","title":"Neurobiology of Bulimia Nervosa","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2020-02-24","conditions":"Bulimia Nervosa","enrollment":10},{"nctId":"NCT02663908","phase":"PHASE3","title":"A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-04-19","conditions":"Prostate Cancer","enrollment":545},{"nctId":"NCT02770391","phase":"PHASE2","title":"Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2016-10-17","conditions":"Prostate Cancer","enrollment":54},{"nctId":"NCT00005044","phase":"PHASE3","title":"Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-02","conditions":"Prostate Cancer","enrollment":1579},{"nctId":"NCT04331717","phase":"PHASE2","title":"Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-11-16","conditions":"Prostate Adenocarcinoma, Obesity, Morbid","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20020221","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19980630","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20010921","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19970627","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20250910","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20230127","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20120328","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19950922","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20090602","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19940721","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20040112","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20210212","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19940214","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20020920","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20120123","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20000512","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20020523","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19990813","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20011114","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19980409","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19901022","type":"ORIG","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20010301","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19960912","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20250910","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20110614","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19950811","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20101029","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19951026","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20050915","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19941107","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20131030","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20010124","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"19940426","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20071031","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20040115","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20000511","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20050915","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020011"},{"date":"20100428","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20190304","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20131108","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20000511","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20050915","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20110617","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"19980729","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20100428","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20040112","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20110617","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"19961203","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20020920","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20020523","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20010301","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20250818","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20231204","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"19951222","type":"ORIG","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20160211","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20100428","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20220418","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20130710","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20000512","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20181210","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20050915","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20120718","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"19990813","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20110617","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20110114","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"19971223","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"19970530","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20030909","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20010723","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20240321","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20160606","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20140627","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20010124","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020517"},{"date":"20011114","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"19980729","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20010921","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"19971223","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20200318","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20131030","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20071031","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20250910","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20040112","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20110614","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20010124","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20020920","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20101029","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20000511","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20020523","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"19990211","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20050915","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20010723","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"19980409","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"19970904","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20010301","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20090602","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20180418","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20250910","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20120123","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20120328","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20000512","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"19970307","type":"ORIG","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20040115","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"19990813","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20050915","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020708"},{"date":"20130514","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20230414","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"19950811","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20111008","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"19951026","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20100830","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"19941107","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20020516","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20090624","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20010806","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20031223","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20010126","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20000511","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20250923","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"19980630","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20250522","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20211112","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20231204","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"19970110","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20200407","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"19950922","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20210311","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20110815","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"19950324","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20220422","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20060216","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20170519","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"19940214","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20051109","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"19940121","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20020308","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20040302","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20080731","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20031028","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20000512","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"19930416","type":"ORIG","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20020924","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"19990813","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20251114","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"19970627","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20210311","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA020263"},{"date":"20231204","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19951026","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20120217","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19940214","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20190304","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20100428","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20250818","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20160606","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19920326","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20040112","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20130710","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20000512","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20020920","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19990813","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20020523","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19980630","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19890126","type":"ORIG","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20010301","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19980109","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19950922","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20240321","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19941108","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20220418","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20110114","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19940426","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20050915","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20181210","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20100428","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20050915","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20140627","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20010124","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19901214","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20000511","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20100428","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20030909","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19991004","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"20020221","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19970627","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"},{"date":"19950811","type":"SUPPL","sponsor":"ABBVIE ENDOCRINE INC","applicationNumber":"NDA019732"}],"publicationCount":62,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Leuprolide","Leuprolide acetate"],"phase":"marketed","status":"active","brandName":"Lupron Depot","genericName":"Lupron Depot","companyName":"University of Michigan Rogel Cancer Center","companyId":"university-of-michigan-rogel-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lupron Depot is a gonadotropin-releasing hormone (GnRH) agonist that suppresses testosterone and estrogen production by desensitizing the pituitary gland. Used for Advanced prostate cancer, Endometriosis, Uterine fibroids.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"1989-01-26T00:00:00.000Z","mah":"ABBVIE ENDOCRINE INC","brand_name_local":null,"application_number":"NDA019732"},{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"1990-10-22T00:00:00.000Z","mah":"ABBVIE ENDOCRINE INC","brand_name_local":null,"application_number":"NDA020011"},{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"1993-04-16T00:00:00.000Z","mah":"ABBVIE ENDOCRINE INC","brand_name_local":null,"application_number":"NDA020263"},{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"1995-12-22T00:00:00.000Z","mah":"ABBVIE ENDOCRINE INC","brand_name_local":null,"application_number":"NDA020517"},{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"1997-03-07T00:00:00.000Z","mah":"ABBVIE ENDOCRINE INC","brand_name_local":null,"application_number":"NDA020708"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}